A recent study conducted by Dr. med. Michael Winkelmann and his colleagues at the LMU Klinikum München explored the association between TGR dynamics from pre-treatment to post-treatment imaging and the patients' outcomes.
The research provides valuable insights into the potential of TGR as a novel prognostic imaging biomarker in the context of CAR-T therapy for patients with relapsed or refractory non-Hodgkin's lymphoma.
Study with mint Lesion™ Uncovers the Impact of Tumor Growth Rate in Predicting the Efficacy of CAR-T-cell Therapy in Lymphoma Patients
Related Resources
Related Resources
University Hospital Tübingen: Neuro-Oncological Imaging with Deep Learning Reconstruction (DLR)
A recent study conducted by the University Hospital of Tübingen investigated the potential of deep learning reconstruction (DLR) in magnetic resonance…
Project RACOON-RESCUE: Advancing Diagnosis and Treatment for Pediatric Non-Hodgkin Lymphoma
Pediatric Non-Hodgkin Lymphoma (NHL), a type of lymph node cancer, is the fourth most common tumor in children and adolescents. Radiological…
Streamline Prostate Cancer Screenings with Prostate.Carcinoma.ai in mint Lesion
The Prostate.Carcinoma.ai plug-in, developed by our partner FUSE-AI, is a powerful addition to mint Lesion, designed specifically to enhance prostate…